Literature DB >> 7852324

Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR.

N A McMillan1, B W Carpick, B Hollis, W M Toone, M Zamanian-Daryoush, B R Williams.   

Abstract

The interferon-induced, double-stranded RNA (dsRNA)-dependent protein kinase, PKR, is an inhibitor of translation and has antiviral, antiproliferative, and antitumor properties. Previously, the dsRNA binding domain had been located within the N-terminal region of PKR and subsequently shown to include two nearly identical domains comprising residues 55-75 and 145-166. We have undertaken both random and site-directed, alanine-scanning mutagenesis in order to investigate the contribution of individual amino acids within these domains to dsRNA binding. Here we identify 2 residues that were absolutely required for dsRNA binding, glycine 57 and lysine 60. Mutation of 2 other residues within the domain (lysine 64 and leucine 75) resulted in less than 10% binding (compared to wild type). We have also identified a number of other residues that influence dsRNA binding to varying degrees. Mutants that were unable to bind dsRNA were not active in vitro and possessed no antiproliferative activity in vivo. However, dsRNA binding mutants were partially transdominant over wild type PKR in mammalian cells, suggesting that binding of dsRNA activator is not the mechanism responsible for the phenotype of PKR mutants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852324     DOI: 10.1074/jbc.270.6.2601

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Chimeric double-stranded RNA-specific adenosine deaminase ADAR1 proteins reveal functional selectivity of double-stranded RNA-binding domains from ADAR1 and protein kinase PKR.

Authors:  Y Liu; M Lei; C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Modulation of RNA editing by functional nucleolar sequestration of ADAR2.

Authors:  Christopher L Sansam; K Sam Wells; Ronald B Emeson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

3.  Substrate-dependent contribution of double-stranded RNA-binding motifs to ADAR2 function.

Authors:  Ming Xu; K Sam Wells; Ronald B Emeson
Journal:  Mol Biol Cell       Date:  2006-05-03       Impact factor: 4.138

4.  Double-stranded RNA-activated protein kinase (PKR) is negatively regulated by 60S ribosomal subunit protein L18.

Authors:  K U Kumar; S P Srivastava; R J Kaufman
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo.

Authors:  R C Patel; P Stanton; N M McMillan; B R Williams; G C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation.

Authors:  S Nanduri; B W Carpick; Y Yang; B R Williams; J Qin
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

7.  Mutational analysis of the vaccinia virus E3 protein defines amino acid residues involved in E3 binding to double-stranded RNA.

Authors:  C K Ho; S Shuman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  PACT, a protein activator of the interferon-induced protein kinase, PKR.

Authors:  R C Patel; G C Sen
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

9.  Potential role for snoRNAs in PKR activation during metabolic stress.

Authors:  Osama A Youssef; Sarah A Safran; Takahisa Nakamura; David A Nix; Gökhan S Hotamisligil; Brenda L Bass
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

10.  An ADAR that edits transcripts encoding ion channel subunits functions as a dimer.

Authors:  Angela Gallo; Liam P Keegan; Gillian M Ring; Mary A O'Connell
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.